Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

CSTL

Castle Biosciences (CSTL)

Castle Biosciences Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:CSTL
일자시간출처헤드라인심볼기업
2024/06/0507:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
2024/05/3105:30Business WireCastle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging SurveillanceNASDAQ:CSTLCastle Biosciences Inc
2024/05/3005:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
2024/05/3005:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
2024/05/3005:30Business WireNew Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of MetastasisNASDAQ:CSTLCastle Biosciences Inc
2024/05/2905:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
2024/05/2905:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
2024/05/2905:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
2024/05/2905:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
2024/05/2505:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CSTLCastle Biosciences Inc
2024/05/1520:00Business WireCastle Biosciences to Present at the Leerink Partners Healthcare Crossroads ConferenceNASDAQ:CSTLCastle Biosciences Inc
2024/05/1420:00Business WireCastle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024NASDAQ:CSTLCastle Biosciences Inc
2024/05/1104:14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CSTLCastle Biosciences Inc
2024/05/1020:00Business WireCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”NASDAQ:CSTLCastle Biosciences Inc
2024/05/0905:30Business WireLargest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class ResultNASDAQ:CSTLCastle Biosciences Inc
2024/05/0320:00Business WireDecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and NeckNASDAQ:CSTLCastle Biosciences Inc
2024/05/0305:05Business WireCastle Biosciences Reports First Quarter 2024 ResultsNASDAQ:CSTLCastle Biosciences Inc
2024/05/0105:30Business WireCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT MelanomaNASDAQ:CSTLCastle Biosciences Inc
2024/04/1120:00Business WireCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024NASDAQ:CSTLCastle Biosciences Inc
2024/04/1106:00Business WireCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsNASDAQ:CSTLCastle Biosciences Inc
2024/04/1020:00Business WireCastle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearNASDAQ:CSTLCastle Biosciences Inc
2024/04/0505:30Business WirePresentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin CancerNASDAQ:CSTLCastle Biosciences Inc
2024/04/0220:00Business WireCastle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:CSTLCastle Biosciences Inc
2024/03/2806:00Business WireCastle Biosciences Announces Updates to its Board of DirectorsNASDAQ:CSTLCastle Biosciences Inc
2024/03/2520:00Business WireCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive YearNASDAQ:CSTLCastle Biosciences Inc
2024/03/2305:30Business WireLong-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNBNASDAQ:CSTLCastle Biosciences Inc
2024/03/1920:00Business WireLeading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation TherapyNASDAQ:CSTLCastle Biosciences Inc
2024/03/1605:30Business WireNew Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and OlderNASDAQ:CSTLCastle Biosciences Inc
2024/03/1220:00Business WireCastle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor ForumNASDAQ:CSTLCastle Biosciences Inc
2024/03/0906:30Business WireCastle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:CSTLCastle Biosciences Inc
 검색 관련기사 보기:NASDAQ:CSTL

최근 히스토리

Delayed Upgrade Clock